Skip to content
Peptide research

AOD-9604

Also known as Anti-Obesity Drug 9604 · Tyr-hGH Fragment 177-191
Category
Weight Management & Metabolic
Administration routes
Injectable
Regulatory status
Not FDA-approved

A modified fragment of human growth hormone marketed for fat loss, said to boost fat breakdown without raising IGF-1 or blood sugar. The mechanism is solid, but the human case is weak: its pivotal trial failed to reach significance, and cartilage-repair claims stay speculative. The FDA has flagged impurity and immune-reaction concerns in compounded batches, and most supply is unregulated research-grade product. Not FDA-approved, banned in sport under WADA.

This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer

Compiled from published research indexed through March 2026.

Overview

AOD-9604 (Anti-Obesity Drug 9604) is a synthetic 16-amino-acid peptide derived from a small section of human growth hormone. It was designed to isolate growth hormone's fat-burning properties without its muscle-building, growth-promoting, or blood sugar-raising effects. Developed in Australia in the 1990s, it completed six human clinical trials with over 900 participants but ultimately failed its main efficacy trial and drug development was halted in 2007. A sponsor announced a self-affirmed conditional food-use GRAS determination in June 2012; this was not an FDA approval.

How it works in the body

A modified fragment of human growth hormone (amino acids 176-191, with an added tyrosine at position 176) that stimulates fat breakdown (lipolysis) without affecting blood sugar or growth. It tells fat cells to release stored fat while blocking the formation of new fat. Beta-3 adrenergic signaling is implicated in animal studies, but its molecular target remains uncertain.

Research overview

AOD-9604's molecular target remains uncertain; animal studies implicate changes in beta-3 adrenergic receptor expression, stimulating fat breakdown and blocking new fat production without raising IGF-1 levels or affecting blood sugar. In animal studies, it reduced weight gain by over 50% in obese mice. An early 12-week human trial showed subjects on 1 mg/day lost 2.6 kg versus 0.8 kg on placebo. However, the larger pivotal 24-week trial with 536 obese adults failed to show statistically significant weight loss compared to placebo, which ended its development as a prescription drug. Comprehensive safety testing found no genotoxic or significant toxicity concerns. A 2015 animal study showed AOD-9604 injected into joints with hyaluronic acid improved cartilage repair in an osteoarthritis model.

Who researches AOD-9604?

Commonly researched by

  • People researching weight management options

    Studied for effects on body composition, appetite regulation, or metabolic rate.

  • People researching blood sugar regulation

    Studied for effects on insulin sensitivity, glucose metabolism, or glycemic control.

Important considerations for

  • Those who are pregnant or breastfeeding

    Absolute

    No reproductive safety data.

  • Anyone under 18

    Absolute

    No pediatric data.

Safety & interactions

General cautions

  • Pregnancy

    Absolute

    No reproductive safety data.

  • Children under 18

    Absolute

    No pediatric data.

How to read the ratings

Benefits
= confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)
Risks
= level of concern: High · Moderate · Low · Theoretical
Interactions
= direction with this peptide: Protective / Synergistic · Caution · Neutral

Risk summary(11)

Rated by level of concern

  • Failed to demonstrate statistically significant weight loss in pivotal Phase IIb clinical trial

    High

    Sponsor (Metabolic Pharmaceuticals) Phase 2b announcements and secondary reporting; no peer-reviewed publication of results exists. Context in Stier, Vos, Kenley. J Endocrinol Metab 2013 https://www.jofem.org/index.php/jofem/article/view/157

  • FDA has cited concerns about potential immunogenicity (immune reactions to the peptide)

    Moderate

    FDA, bulk drug substances nominated for use in compounding under section 503A https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-nominated-use-compounding-under-section-503a-federal-food-drug-and-cosmetic-act

  • FDA has cited concerns about peptide impurity profiles in compounded formulations

    Moderate

    FDA 503A bulks nomination evaluation https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-nominated-use-compounding-under-section-503a-federal-food-drug-and-cosmetic-act

  • Limited long-term safety data beyond 24-week trial duration

    Moderate

    Stier, Vos, Kenley. J Endocrinol Metab 2013;3(1-2):7-15 https://www.jofem.org/index.php/jofem/article/view/157

  • Injection site irritation (subcutaneous administration)

    Low

    Extrapolation from general SC peptide administration; route of the clinical program per Stier 2013 https://www.jofem.org/index.php/jofem/article/view/157 (no AOD-9604-specific injection-site data published)

  • Transient headache reported in some trial participants

    Low

    Stier, Vos, Kenley. J Endocrinol Metab 2013;3(1-2):7-15 https://www.jofem.org/index.php/jofem/article/view/157

  • Mild flu-like symptoms reported in some trial participants

    Theoretical

    No source located supporting a flu-like syndrome in AOD-9604 trials; trial adverse-event profile per Stier 2013 https://www.jofem.org/index.php/jofem/article/view/157

  • No data on safety during pregnancy or lactation

    Moderate

    Absence of published reproductive/developmental data; trial population per Stier 2013 https://www.jofem.org/index.php/jofem/article/view/157

  • Quality control concerns with unregulated products sold online

    High

    FDA 503A bulks nomination evaluation https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-nominated-use-compounding-under-section-503a-federal-food-drug-and-cosmetic-act

  • Potential for degradation and loss of efficacy if improperly stored (peptide stability concerns)

    Low

    Mechanistic/general peptide handling; aggregation concern noted in FDA 503A evaluation https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-nominated-use-compounding-under-section-503a-federal-food-drug-and-cosmetic-act

  • Prohibited in competitive sports — positive WADA test could result in sanctions

    High

    WADA statement on the substance AOD-9604 https://www.wada-ama.org/en/news/wada-statement-substance-aod-9604

Interaction summary(8)

Rated by direction with this peptide

  • Beta-3 adrenergic receptor agonists (e.g. mirabegron)

    SynergisticTheoretical

    AOD-9604's lipolytic effect is abolished in beta3-AR knockout mice and it restores suppressed beta3-AR expression in obese mice, so a beta3 agonist would act on the same pathway. Entirely mechanism-derived from animal work; no human co-administration study exists, and AOD-9604 showed no fat-loss efficacy in humans, so any 'synergy' is additive only in theory.

    Heffernan et al., Endocrinology 2001;142(12):5182-9 https://academic.oup.com/endo/article/142/12/5182/2988749

  • Beta-blockers, particularly non-selective agents

    CautionTheoretical

    Loss-of-effect rather than a safety hazard: because the lipolytic mechanism requires an intact beta3-adrenergic pathway, adrenergic blockade would plausibly blunt any fat-mobilizing response. Note most clinical beta-blockers are beta1/beta2-selective with limited beta3 activity, and this has never been tested clinically with AOD-9604.

    Mechanism inferred from beta3-AR dependence in Heffernan et al., Endocrinology 2001 https://academic.oup.com/endo/article/142/12/5182/2988749

  • Sympathomimetic stimulants (caffeine, ephedrine, clenbuterol, amphetamines)

    CautionTheoretical

    Additive adrenergic and lipolytic stimulation is plausible in principle, but no interaction study exists and AOD-9604 itself produced no clinically significant vital-sign or ECG changes in the trial program. When AOD-9604 is used with a stimulant, cardiovascular risk derives from the stimulant, not from AOD-9604.

    Mechanistic; AOD-9604 cardiovascular safety baseline from Stier 2013 https://www.jofem.org/index.php/jofem/article/view/157

  • Insulin, sulfonylureas and other glucose-lowering agents

    NeutralTheoretical

    Unlike full-length hGH, AOD-9604 showed no adverse effect on oral glucose tolerance in randomized placebo-controlled human testing, so no anticipatory antidiabetic dose adjustment is indicated. No trial enrolled diabetic or insulin-treated patients, so this is extrapolation from a non-diabetic population; routine glucose monitoring remains sensible.

    Stier, Vos, Kenley. J Endocrinol Metab 2013;3(1-2):7-15 https://www.jofem.org/index.php/jofem/article/view/157

  • Recombinant human growth hormone and GH secretagogues (CJC-1295, ipamorelin, tesamorelin)

    CautionTheoretical

    Using a GH fragment with agents that raise endogenous or exogenous GH reintroduces the IGF-1 elevation and glucose impairment that AOD-9604 was engineered to avoid, so the fragment's clean metabolic profile cannot be assumed to carry over. No co-administration study exists; the caution is inferred from the known effects of the co-administered agents, not from any AOD-9604 interaction data.

    Contrast between fragment and full-length hGH established in Stier 2013 https://www.jofem.org/index.php/jofem/article/view/157; no interaction study located

  • Intra-articular hyaluronic acid

    SynergisticTheoretical

    In a single collagenase-induced rabbit knee OA model, intra-articular AOD9604 combined with hyaluronic acid outperformed either agent alone on cartilage morphology and histopathology. Animal-only, single study, intra-articular route; there is no human confirmation and no clinical use of this combination.

    Kwon & Park, Ann Clin Lab Sci 2015;45(4):426-32 (rabbit model)

  • GLP-1 receptor agonists (semaglutide, tirzepatide)

    NeutralTheoretical

    Mechanisms are non-overlapping (incretin/appetite signaling versus adipocyte beta3-mediated lipolysis) and no pharmacokinetic interaction is expected, but there is zero co-administration data and AOD-9604 contributed no proven weight loss of its own in Phase IIb - so it adds cost and uncertainty rather than demonstrated benefit to a GLP-1 regimen.

    No published interaction data; negative AOD-9604 Phase IIb weight outcome (sponsor reporting, unpublished)

  • Anti-doping testing in sanctioned competition

    CautionHigh

    Not a pharmacological interaction but the highest-probability real-world harm: WADA holds AOD-9604 prohibited at all times under S0 as a non-approved substance, so use by a tested athlete risks sanction regardless of dose or route.

    WADA statement on the substance AOD-9604 https://www.wada-ama.org/en/news/wada-statement-substance-aod-9604

Known risks(11)

  • Failed to demonstrate statistically significant weight loss in pivotal Phase IIb clinical trial

  • FDA has cited concerns about potential immunogenicity (immune reactions to the peptide)

  • FDA has cited concerns about peptide impurity profiles in compounded formulations

  • Limited long-term safety data beyond 24-week trial duration

  • Injection site irritation (subcutaneous administration)

  • Transient headache reported in some trial participants

  • Mild flu-like symptoms reported in some trial participants

  • No data on safety during pregnancy or lactation

  • Quality control concerns with unregulated products sold online

  • Potential for degradation and loss of efficacy if improperly stored (peptide stability concerns)

  • Prohibited in competitive sports — positive WADA test could result in sanctions

Drug interactions(5)

  • Growth Hormone (HGH/Somatropin)

    Theoretical — avoid co-administration

    Theoretical additive or competitive interaction — both act on overlapping lipolytic pathways. Co-administration has not been studied and is not recommended.

  • Beta-3 Adrenergic Agonists (e.g., mirabegron)

    Theoretical — use caution

    AOD-9604 modulates beta-3-AR expression. Co-administration with beta-3 agonists could theoretically potentiate adrenergic effects.

  • Insulin and Oral Hypoglycemics

    Low risk — monitor glucose

    While AOD-9604 has not shown effects on glucose homeostasis in studies, patients on diabetes medications should monitor blood glucose when initiating any metabolic peptide.

  • Other Lipolytic Peptides (e.g., CJC-1295, Tesamorelin, GHRP-6)

    Unknown — no formal studies

    No formal interaction studies exist. Using multiple lipolytic peptides together lacks evidence-based safety data.

  • Corticosteroids

    Pharmacological antagonism — may reduce efficacy

    Chronic corticosteroid use promotes adipogenesis and could counteract the lipolytic effects of AOD-9604.

Research & benefits

Evidence base

Total Studies
20
Human Studies
6

Researched for(10)

Rated by confidence in the evidence

  • Stimulates lipolysis (fat breakdown) in adipose tissue without affecting muscle mass

    Low

    Animal and cell studies show fat breakdown; human muscle mass effects remain unmeasured.

    Heffernan et al., Endocrinology 2001;142(12):5182-9 https://academic.oup.com/endo/article/142/12/5182/2988749; Ng et al., Horm Res 2000;53:274-8

  • Inhibits lipogenesis (new fat formation/de novo fatty acid synthesis)

    Low

    Reduced fat formation seen in animal and cell studies only, not tested in humans.

    Ng et al., Horm Res 2000;53:274-8; Heffernan et al., Endocrinology 2001;142(12):5182-9 https://academic.oup.com/endo/article/142/12/5182/2988749

  • Does not elevate IGF-1 levels, unlike full-length HGH

    High

    Confirmed across multiple human trials measuring IGF-1 directly, with no rise versus placebo.

    Stier, Vos, Kenley. Safety and Tolerability of the Hexadecapeptide AOD9604 in Humans. J Endocrinol Metab 2013;3(1-2):7-15 https://www.jofem.org/index.php/jofem/article/view/157

  • Does not impair glucose homeostasis or insulin sensitivity

    High

    Human trials found no adverse effect on glucose tolerance over 24 weeks; improvement unproven.

    Stier, Vos, Kenley. J Endocrinol Metab 2013;3(1-2):7-15 https://www.jofem.org/index.php/jofem/article/view/157

  • Does not suppress the HPA axis

    Speculative

    Untested claim, based on mechanism only; no study measured cortisol or HPA axis response.

    Mechanistic inference plus general safety labs in Stier 2013 (https://www.jofem.org/index.php/jofem/article/view/157); no direct HPA-axis study located - no source directly supports this claim

  • Generally favorable short-term tolerability in IV and oral trials; subcutaneous safety remains unestablished

    High

    Six randomized human trials in about 900 subjects found tolerability similar to placebo.

    Stier, Vos, Kenley. J Endocrinol Metab 2013;3(1-2):7-15 https://www.jofem.org/index.php/jofem/article/view/157

  • May support cartilage repair and regeneration (proteoglycan and collagen synthesis stimulation)

    Speculative

    Based on a single small rabbit study; no human trials, mechanism unconfirmed.

    Kwon & Park, Ann Clin Lab Sci 2015;45(4):426-32 (rabbit OA model)

  • Orally bioavailable (unlike most peptides), though subcutaneous injection is also used

    Low

    Oral dosing was used in trials, but absolute oral bioavailability was never established.

    Stier, Vos, Kenley. J Endocrinol Metab 2013;3(1-2):7-15 https://www.jofem.org/index.php/jofem/article/view/157

  • No observed cardiovascular adverse events in clinical trials

    Medium

    No cardiovascular signal in short human trials, which were not designed for heart safety.

    Stier, Vos, Kenley. J Endocrinol Metab 2013;3(1-2):7-15 https://www.jofem.org/index.php/jofem/article/view/157

  • Selectively targets fat metabolism without broader growth-promoting hormonal effects

    Low

    Hormonal neutrality shown in humans, but fat-targeting effect rests only on animal data.

    Stier 2013 https://www.jofem.org/index.php/jofem/article/view/157 (IGF-1/glucose); Heffernan et al., Endocrinology 2001 https://academic.oup.com/endo/article/142/12/5182/2988749 (animal lipolysis)

Benefits(10)

  • Stimulates lipolysis (fat breakdown) in adipose tissue without affecting muscle mass

  • Inhibits lipogenesis (new fat formation/de novo fatty acid synthesis)

  • Does not elevate IGF-1 levels, unlike full-length HGH

  • Does not impair glucose homeostasis or insulin sensitivity

  • Does not suppress the HPA axis

  • Favorable safety profile across extensive preclinical and clinical testing (900+ participants)

  • May support cartilage repair and regeneration (proteoglycan and collagen synthesis stimulation)

  • Orally bioavailable (unlike most peptides), though subcutaneous injection is also used

  • No observed cardiovascular adverse events in clinical trials

  • Selectively targets fat metabolism without broader growth-promoting hormonal effects

Key studies(6)

  1. Heffernan M, Summers RJ, Thorburn A, Ogru E, Gianello R, Jiang WJ, Ng FM

    Endocrinology

    2001

    Demonstrated that AOD-9604 and HGH increase beta-3-AR RNA expression in obese mice to lean levels. Knockout mice lacked the chronic weight and lipolysis responses but retained acute energy-expenditure and fat-oxidation responses, indicating a more complex mechanism.

  2. Ng FM, Sun J, Sharma L, Libinaka R, Jiang WJ, Gianello R

    Hormone Research

    2000

    Oral AOD-9604 at 500 mcg/kg/day for 19 days reduced weight gain by over 50% in obese rats with no adverse effect on insulin sensitivity.

  3. More MI, Kenley D

    Journal of Endocrinology and Metabolism

    2014

    Comprehensive safety review: no genotoxicity across Ames test, chromosome aberration assays. NOAEL of 100 mg/kg/day (rats, 6 months) and 50 mg/kg/day (monkeys, 9 months). Supports GRAS designation.

  4. Kwon DR, Park GY

    Annals of Clinical and Laboratory Science

    2015

    Combined AOD-9604 + hyaluronic acid intra-articular injection was more effective than either alone at reducing cartilage deterioration and lameness in rabbit OA model.

  5. Misra M

    Current Cardiology Reviews

    2013

    Comprehensive review documenting AOD-9604 Phase IIb failure: 24-week trial of 536 subjects failed to show significant weight loss. Classified AOD-9604 as a failed drug candidate.

  6. Wilding J

    Current Opinion in Investigative Drugs

    2004

    Review of AOD-9604 development status as of 2004, documenting Phase IIa trial progress for obesity treatment.

What research suggests over time

  • Weeks 2-4

    Phase IIb

    No significant short-term effects in published human trials.

  • Months 2-3

    Phase IIb (negative)

    Phase IIb obesity trial: failed to demonstrate statistically significant weight loss vs placebo at 12 weeks.

  • Long-term

    Phase IIb (negative)

    A conditional food-use GRAS determination was self-affirmed in 2012; this does not establish therapeutic approval or fat-loss efficacy. Still sold as an unregulated product despite the negative trial result.

Regulation & availability

Why researchers look at it

Tested in over 900 people across six clinical trials with an excellent safety profile, but its pivotal 536-person Phase IIb weight loss trial failed to reach statistical significance and development was halted in 2007. A 2015 animal study showing improved cartilage repair when injected into joints has opened a potential second life for the compound. If the cartilage repair pathway advances to human trials, AOD-9604 could find the clinical niche that eluded it in obesity.

Estimated cost
No approved product and no verified reference price
FDA status
AOD-9604 is not FDA-approved and is not eligible for compounding: it is not on FDA's list of bulk substances pharmacies may use, and an FDA advisory committee voted against adding it in December 2024. On December 4, 2024, PCAC voted 0–12 against inclusion.
WADA status
Prohibited in competition and out-of-competition. Listed under WADA S2 category (Peptide Hormones, Growth Factors, Related Substances, and Mimetics). Athletes subject to anti-doping testing should not use AOD-9604.
Prescribability
AOD-9604 is not FDA-approved and is not eligible for compounding: it is not on FDA's list of bulk substances pharmacies may use, and an FDA advisory committee voted against adding it in December 2024.
Availability
No approved pharmaceutical product was verified. Some clinics and pharmacies offer AOD-9604, but no qualifying US bulk-compounding basis was established: its nominations were withdrawn and it is absent from Category 1 and the 503A Bulks List. The food-use GRAS claim was self-affirmed in 2012, not granted by FDA in 2021. Australian approval for a cartilage-repair product has not been verified.

International status

  • EU

    Not approved

  • US

    AOD-9604 is not FDA-approved and is not eligible for compounding: it is not on FDA's list of bulk substances pharmacies may use, and an FDA advisory committee voted against adding it in December 2024.

  • Australia

    Developed at Monash University; available via compounding

Regulatory timeline(13)

  1. 1990s
    AOD-9604 developed by Metabolic Pharmaceuticals Ltd. (Melbourne, Australia) as a synthetic fragment of HGH amino acids 176-191.
  2. 2000
    Ng et al. publish preclinical metabolic studies showing 50%+ weight gain reduction in obese rats (PMID: 11146367).
  3. 2001
    Heffernan et al. publish beta-3-AR mechanism study in Endocrinology (PMID: 11713213).
  4. 2002
    Phase IIa clinical trials commence for oral AOD-9604 in obese adults.
  5. 2004
    Wilding reviews AOD-9604 development progress in Current Opinion in Investigative Drugs (PMID: 15134286).
  6. 2007
    Pivotal Phase IIb trial (24 weeks, 536 obese subjects) fails to meet primary efficacy endpoint of statistically significant weight loss.
  7. 2007-02-21
    Metabolic Pharmaceuticals Ltd. terminates AOD-9604 drug development program.
  8. 2014
    More & Kenley publish comprehensive safety/metabolism review supporting nutraceutical use (DOI: 10.14740/jem213w).
  9. 2015
    Kwon & Park publish cartilage repair study in rabbit OA model, showing efficacy with hyaluronic acid (PMID: 26275694).
  10. 2012-06-25
    Calzada announces a self-affirmed conditional food-use GRAS determination by an expert panel. This is not an FDA-issued approval.
  11. 2018
    Widespread adoption in US compounding pharmacy and peptide therapy clinics for unapproved fat loss and joint health applications.
  12. 2024
    FDA PCAC meeting: FDA proposes NOT to include AOD-9604 on the 503A Bulks List for pharmaceutical compounding, citing immunogenicity concerns, impurity profiles, and limited long-term data.
  13. 2025
    Regulatory dispute ongoing. Compounding pharmacy advocates and clinicians challenge FDA decision. Final determination pending.

Sources & FAQs

Research sources(8)

Frequently asked questions(6)

What is AOD-9604 and how does it differ from HGH?

AOD-9604 is a 16-amino acid synthetic peptide derived from amino acids 176-191 of human growth hormone, with an added tyrosine residue. Unlike full HGH, it selectively promotes fat metabolism without elevating IGF-1, affecting glucose levels, promoting cell growth, or causing the diabetogenic effects associated with HGH therapy.

Did AOD-9604 work in clinical trials?

It showed modest results. In a 12-week Phase IIa trial, the oral peptide produced 2.6 kg weight loss vs 0.8 kg on placebo. However, the pivotal 24-week Phase IIb trial with 536 subjects failed to meet its primary endpoint of statistically significant weight loss, and drug development was terminated in 2007.

Is AOD-9604 safe?

AOD-9604 has one of the most extensive safety dossiers of any peptide. Six clinical trials with 900+ participants showed adverse events comparable to placebo. Preclinical toxicology (6-month rat, 9-month monkey studies) found no genotoxicity or significant toxicological concerns. However, the FDA has cited concerns about long-term safety data gaps, peptide impurities, and potential immunogenicity.

Is AOD-9604 legal?

AOD-9604 is not FDA-approved. Its food-use GRAS claim came from a self-affirmed conditional determination, which does not authorize therapeutic use. Its compounding nominations were withdrawn, and it is not in Category 1 or the 503A Bulks List. WADA prohibits it at all times. Legal controls depend on jurisdiction.

Can AOD-9604 help with joint problems?

Evidence is limited to animal research. A 2015 study showed intra-articular AOD-9604 combined with hyaluronic acid reduced cartilage deterioration in a rabbit osteoarthritis model; it does not establish human benefit. A TGA-approved cartilage-repair product has not been verified.

How is AOD-9604 typically administered?

In clinical trials, AOD-9604 was given orally. In clinical practice settings, subcutaneous injection is common.